Nonspecific vaginitis (NSV) is a common and still incompletely understood condition characterized by increased and malodorous vaginal discharge not associated with Trichomonas vaginalis or yeast infections. Early studies suggested an etiological role for Haemophilus vaginalis (4) . This role has since been disputed by some and supported by others. Pheifer et al. (7) found that 17 of 18 women with characteristic symptoms and signs of NSV, but only one of 18 matched normal women, had positive cultures for H. vaginalis. An association of NSV with quantitatively increased growth of anaerobes from vaginal secretions was also noted (7 Treatment. Patients were treated with 500 mg of erythromycin orally four times daily for 7 days. They were asked to refrain from sexual intercourse during therapy and return for follow-up visits at 7 days, 3 weeks, and 6 weeks. At each follow-up visit, patients were reexamined as during the initial visit. Those discontinuing erythromycin therapy due to side effects or requiring retreatment at the completion of therapy or thereafter because of persistent signs and symptoms were treated with 500 mg of metronidazole twice daily for 7 days.
Antibiotic susceptibility testing. The in vitro susceptibility of 27 isolates of H. vaginalis obtained from women with NSV was determined for erythromycin by the standard agar dilution method (10) at pH 5.0, 5.5, 6.0, 6.5, and 7.0. The pH was adjusted with hydrochloric acid and sodium hydroxide after media had been autoclaved and antibiotics had been added. Peptone-starch-dextrose agar (3) was used in place of Mueller-Hinton agar, which does not support growth of H. vaginalis. Plates were inoculated with a Steers replicator, incubated in a C02 incubator containing approximately 5% C02 in air at 350C, and examined at 48 h for minimal inhibitory concentrations.
RESULTS
Therapy results. Four patients discontinued erythromycin therapy early in the course of treatment due to nausea, cramping, or diarrhea or all of these. Three others experienced mild nausea or diarrhea, or both, but continued therapy.
All 17 patients were initially culture positive for H. vaginalis and negative for N. gonorrhoeae. As Thus, 14 patients, including 10 with persistent or relapsing NSV and 4 who could not comply with treatment, were retreated with metronidazole. All 14 became culture negative for H. vaginalis and free of symptoms and signs of NSV after 7 days of metronidazole therapy. Eight were reexamined 3 to 6 weeks after treatment, and all remained culture negative and free of symptoms and signs of NSV.
Susceptibility testing results. Mininal inhibitory concentrations (MICs) of erythromycin for the 27 strains of H. vaginalis are shown in Table 2 . Although 26 of 27 strains had MICs of c0.03 jig of erytbromycin per ml at pH 7.0, the MIC of most strains was approximately 10-fold or more higher at pH 5.5. Due to poor growth, MICs could not be determined at pH c5.0.
DISCUSSION
The present study shows erythromycin in an oral dose of 500 mg four times a day for 7 days to be ineffective for NSV, despite high in vitro susceptibility of H. vaginalis to erythromycin at pH 7.0.
The failure of erythromycin to eradicate H. vaginalis in vivo is not fully explained. Erythromycin may achieve low levels in vaginal fluid (1, 3) .
